MEN WITH ISOLATED HIGH GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA (HGPIN) HAVE A HIGH RISK OF PROSTATE CANCER IN LONG-TERM FOLLOW-UP: RESULTS FROM A PROSPECTIVE MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED PROSTATE CANCER PREVENTION TRIAL.

被引：1

作者：

Taneja, Samir S.

Morton, Ronald A.

Barnette, Gary

Hancock, Michael

Brawer, Michael

Steiner, Mitchell S.

机构：

来源：

JOURNAL OF UROLOGY | 2011年 / 185卷 / 04期

关键词：

D O I：

10.1016/j.juro.2011.02.841

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

1206

引用

页码：E484 / E484

页数：1

共 50 条

[1] Double-blind, placebo-controlled trial of toremifene for the prevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia.
Price, D
Stein, B
Goluboff, E
Sieber, P
Bostwick, D
Barnette, G
Boger, R
Steiner, MS
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 106S - 106S
[2] Men with high-grade prostatic intraepithelial neoplasia (HGPIN) remain at high risk for prostate cancer regardless of whether HGPIN is detected on subsequent biopsies
Burzon, D
Kahnoski, RJ
Bennett, JK
Barnette, KG
Steiner, MS
[J]. JOURNAL OF UROLOGY, 2005, 173 (04): : 184 - 184
[3] Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: Results of a double-blind, placebo controlled, phase IIB clinical trial
Price, David
Stein, Barry
Sieber, Paul
Tutrone, Ronald
Bailen, James
Goluboff, Erik
Burzon, Daniel
Bostwick, David
Steiner, Mitchell
[J]. JOURNAL OF UROLOGY, 2006, 176 (03): : 965 - 970
[4] Baseline characteristics validate the inclusion criteria of a phase III comparison of toremifene and placebo for the prevention of prostate cancer in men with isolated high grade prostatic intraepithelial neoplasia (HGPIN)
Taneja, S. S.
[J]. EUROPEAN UROLOGY SUPPLEMENTS, 2008, 7 (03) : 224 - 224
[5] Prospective study confirms men with high grade prostatic intraepithelial neoplasia (PIN) are at high risk for prostate cancer.
Steiner, M
Boger, R
Barnette, G
Mitchell, J
Bostwick, D
Price, D
[J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2004, 13 (11) : 1886S - 1886S
[6] Toremifene for the prevention of prostate cancer among 514 men with high-grade prostatic intraepithelial neoplasia (PIN): Results of a double-blind, placebo-controlled phase IIB trial
Price, D
Stein, B
Goluboff, E
Sieber, P
Bostwick, D
Barnette, KG
Steiner, MS
[J]. JOURNAL OF UROLOGY, 2005, 173 (04): : 188 - 189
[7] EFFICACY OF DUTASTERID IN MEN WITH HIGH GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA - RESULTS OF A PROSPECTIVE RANDOMIZED PLACEBO CONTROLLED STUDY
Reissigl, Andreas
Haffner, Clemens
Neyer, Michael
Wiunig, Christian
Bachmayer, Christan
Pointner, Josef
[J]. JOURNAL OF UROLOGY, 2010, 183 (04): : E772 - E772
[8] Tasquinimod and survival in men with metastatic castration-resistant prostate cancer: Results of long-term follow-up of a randomized phase II placebo-controlled trial
Armstrong, Andrew J.
Haggman, Michael
Stadler, Walter Michael
Gingrich, Jeffrey R.
Assikis, Vasily J.
Polikoff, Jonathan
Denmeade, Samuel R.
George, Daniel J.
Andreou, Cal
Clark, William R.
Sieber, Paul
Agajanian, Richy
Belkoff, Laurence
Damber, Jan-Erik
Nordle, Orjan
Forsberg, Goran
Carducci, Michael Anthony
Pili, Roberto
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[9] Statin use linked with a decrease in the conversion from high-grade prostatic intraepithelial neoplasia (HGPIN) to prostate cancer
Fowke, Jay H.
Motley, Saundra S.
[J]. CARCINOGENESIS, 2018, 39 (06) : 819 - 825
[10] Prospective association between obesity and statin use with conversion from high-grade prostatic intraepithelial neoplasia (HGPIN) to prostate cancer (PC)
Fowke, Jay H.
Motley, Saundra
Byerly, Susan
[J]. CANCER RESEARCH, 2014, 74 (19)

← 1 2 3 4 5 →